- Home
- XRTX vs QLGN Comparison
XRTX vs QLGN Comparison
Compare XRTX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRTX
- QLGN
- Stock Information
- Founded
- XRTX 2011
- QLGN 1996
- Country
- XRTX Canada
- QLGN United States
- Employees
- XRTX N/A
- QLGN 4
- Industry
- XRTX Pharmaceuticals and Biotechnology
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- XRTX Health Care
- QLGN Health Care
- Exchange
- XRTX Nasdaq
- QLGN Nasdaq
- Market Cap
- XRTX 4.4M
- QLGN 7.4M
- IPO Year
- XRTX N/A
- QLGN N/A
- Fundamental
- Price
- XRTX $0.67
- QLGN $3.68
- Analyst Decision
- XRTX
- QLGN
- Analyst Count
- XRTX 0
- QLGN 0
- Target Price
- XRTX N/A
- QLGN N/A
- AVG Volume (30 Days)
- XRTX 6.0M
- QLGN 3.6M
- Earning Date
- XRTX 11-14-2025
- QLGN 11-13-2025
- Dividend Yield
- XRTX N/A
- QLGN N/A
- EPS Growth
- XRTX N/A
- QLGN N/A
- EPS
- XRTX N/A
- QLGN N/A
- Revenue
- XRTX N/A
- QLGN N/A
- Revenue This Year
- XRTX N/A
- QLGN N/A
- Revenue Next Year
- XRTX N/A
- QLGN N/A
- P/E Ratio
- XRTX N/A
- QLGN N/A
- Revenue Growth
- XRTX N/A
- QLGN N/A
- 52 Week Low
- XRTX $0.63
- QLGN $1.61
- 52 Week High
- XRTX $1.79
- QLGN $10.45
- Technical
- Relative Strength Index (RSI)
- XRTX 40.10
- QLGN 47.12
- Support Level
- XRTX $0.63
- QLGN $3.28
- Resistance Level
- XRTX $0.78
- QLGN $4.04
- Average True Range (ATR)
- XRTX 0.09
- QLGN 0.56
- MACD
- XRTX -0.03
- QLGN -0.19
- Stochastic Oscillator
- XRTX 5.13
- QLGN 14.87
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.